Navigation Links
A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer
Date:12/14/2007

support as we accelerate the development of a GP88 blood diagnostic test and our goal of establishing GP88 as the most sensitive and reliable marker for early breast cancer detection," said Ginette Serrero, PhD, CEO of A&G.

About A&G Pharmaceutical (http://www.agrx.net)

A&G Pharmaceutical is a theranostics company creating and developing monoclonal antibodies to cancer-specific targets as a basis for novel therapeutic and diagnostic products. A&G's therapeutics division is pursuing development of anti-GP88 and other monoclonal antibody drugs for cancer. On the diagnostics side, A&G is developing tissue and serum test kits that will improve early detection, diagnosis, and treatment of breast cancer based on GP88. One of the diagnostic products-a biopsy test kit currently in clinical trials-will also serve as a companion diagnostic to anti-GP88 immunotherapy. Early clinical studies validating the tests have been conducted at the University of Maryland Greenebaum Cancer Center and supported by grants from the Maryland Industrial Partnerships (MIPS) program and National Cancer Institute Small Business Innovation Research (SBIR) program. A&G's Precision Antibody(TM) service unit generates revenue to fund the drug development effort by providing customized antibodies to leading pharmaceutical and biotechnology companies as well as federal laboratories. A&G has raised $14 million of equity capital and is located in Columbia, Md.

About the Avon Foundation (http://www.avonfoundation.org)

The Avon Foundation, a 501(c)(3) public charity, was founded in 1955 to improve the lives of women and their families. Now past the half century mark, the Avon Foundation brings this mission to life through two key areas: breast cancer and domestic violence, with support also for emergency and disaster relief for women and their families. Through 2007 Avon glo
'/>"/>

SOURCE A&G Pharmaceutical
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015 HUYA Bioscience International (HUYA) today announced the ... Society of HTLV-1, held this week at the University ... the Society is to promote research on HTLV-1 and ... technology and research related to these fields to advance ... is proud to support this prestigious conference," said ...
(Date:8/27/2015)... RESEARCH TRIANGLE PARK, N.C. , Aug. 27, ... reports on the decision by FedEx, UPS and ... shipments of certain biological specimens classified as ,select ... expertise and long history of handling these sensitive ... network, knowledge of global transportation regulations, trained and ...
(Date:8/26/2015)... WARREN, N.J. , Aug. 26, 2015  Roka ... company focused on providing advanced testing solutions for the ... Thomas, CEO will present at the Sidoti & Company ... The conference will be held at the New York ... the presentation will be available through the investor relations ...
(Date:8/26/2015)... GERMANTOWN, Md. , Aug. 26, 2015 ... synthetic biology, announced today the closing of its previously ... in full by the underwriters of their option to ... the public offering price of $41.00 per share.  The ... of shares of common stock sold by Intrexon to ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Marken Ensures Safe Transportation Of Select Agents And Toxins 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... Life Technologies Corporation (NASDAQ: ... its TaqMan® Mutation Detection Assays -- highly sensitive and ... detect a single mutant molecule hiding in a background ...   http://photos.prnewswire.com/prnh/20110216/MM49339LOGO ) Developed for clinical ...
... new research reveals a potentially highly effective treatment for ... buildup of bone tissue. HO comes in two main ... that strikes wounded military personnel and surgery patients and ... An animal study by developmental biologists shows that ...
... April 1, 2011 Once again, the Annual Report ... a continued decline in diagnoses and deaths for many types ... preventive measures such as cessation of smoking and improved diet, ... But for many cancers, such as the blood cancers, early ...
Cached Biology Technology:One in 1 Million No Longer a Long Shot 2One in 1 Million No Longer a Long Shot 3One in 1 Million No Longer a Long Shot 4One in 1 Million No Longer a Long Shot 5Potential Treatment Found for Debilitating Bone Disease in Wounded Soldiers and Children 2Potential Treatment Found for Debilitating Bone Disease in Wounded Soldiers and Children 3Potential Treatment Found for Debilitating Bone Disease in Wounded Soldiers and Children 4The Leukemia & Lymphoma Society: Accelerating Cures Must Be a Priority 2
(Date:8/17/2015)... OXFORD, Conn. , Aug. 17, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces its new sales campaign for Q4 2015. The ... winning marketing team consisting of Amplitude Marketing Group ( ... Amplitude Marketing Group is a leader in retail driven ...
(Date:8/12/2015)... , August 12, 2015 As ... mobile payment innovation and advanced biometrics technology is accelerating ... way consumers rely on using their credit cards, the ... the future for payment services led by companies in ... ), :  Google, Inc. (NASDAQ: GOOG ), Apple ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... BGI, the world,s largest genomic organization, today announced its ... of RNA-Seq in predicting patient outcomes as part of ... U.S. Food and Drug Administration (FDA). The SEQC, also ... MicroArray Quality Control (MAQC), aimed at assessing the technical ...
... upper and lower abdomen is a reliable, minimally invasive way ... indicator of too much male hormone, researchers report. "We ... women that was as non-intrusive and accurate as possible," said ... Sciences University. "We believe this approach is approximately ...
... controlled by the brain from blood pressure to appetite to ... , a team of scientists led by Dr. Gil Levkowitz of ... brain area in which biochemical commands are passed from the brain ... the process, they discovered a surprising new role for the ,hormone ...
Cached Biology News:BGI to play a pivotal role in demonstrating the superior performance of RNA-Seq 2Women's chin, abdomen are good indicators of excessive hair growth 2Women's chin, abdomen are good indicators of excessive hair growth 3A hormone ensures its future 2
Phospho-FAK (Tyr576/577) Antibody...
... Mouse monoclonal [YPF19] to Yersinia pestis ... detect Yersinia pestis . ... Yersinia pestis vaccine strain ... antibody recognises Y.pestis F1 capsular antigen. ...
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Biology Products: